References
- Veronesi A, Magri M D, Tirelli U. Chemotherapy of advanced non-small cell lung cancer with cyclophosphamide, adriamycin, methotrexate and procarbazine versus cisplatin and etoposide: a randomized study. Am J Clin Oncol 1988; 11: 566–71
- Luedke D W, Einhorn L, Omura G A, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in non small cell lung cancer. A Southeastern Cancer Study Group Trial. J Clin Oncol 1990; 8: 886–91
- Ellis P A, Smith I E, Hardy J R, et al. Symptom relief with MVP(motomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71: 366–70
- Joss R A, Cavalli F, Goldhirsh A, Mernillod B. New agents in non-small cell lung cancer. Cancer Treat Rev 1984; 11: 205–36
- Drings P. Ifosfamide in the treatment of bronchial carcinoma, W P Brade, G A Nagel, S Seeber. Karger, Basel 1987; 294–318
- Ardizzoni A, Addoamo G F, Baldini E, et al. Mitomycin-ifos-famide-cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomized phase II study. Br J Cancer 1995; 71: 115–9
- Miller A B, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
- Shinkai T, Eguchi K, Sasaki Y, et al. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chem-other Pharmacol 1992; 30: 1–6